Browse

Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers

Cited 66 time in Web of Science Cited 68 time in Scopus
Authors
Chung, Jae-Yong; Cho, Joo-Youn; Yu, Kyung-Sang; Kim, Jung-Ryul; Jung, Hye-Ryung; Lim, Kyoung-Soo; Jang, In-Jin; Shin, Sang-Goo
Issue Date
2005-06-18
Publisher
Elsevier
Citation
Clin Pharmacol Ther. 2005 Jun;77(6):486-94.
Keywords
AdultDrug Interactions/geneticsEnzyme Inhibitors/pharmacokinetics/pharmacologyFemaleGenotypeGlucuronosyltransferase/*geneticsHumansHypnotics and Sedatives/*pharmacokinetics/pharmacologyInfusions, IntravenousLorazepam/*pharmacokinetics/pharmacologyMalePolymorphism, GeneticRifampin/pharmacokinetics/pharmacologyValproic Acid/pharmacokinetics/pharmacology
Abstract
OBJECTIVE: Our objective was to investigate the effect of the uridine 5'-diphosphate-glucuronosyltransferase (UGT) 2B15 genetic polymorphism on the pharmacokinetics and pharmacodynamics of lorazepam in basal, inhibited, and induced metabolic states in healthy normal volunteers. METHODS: Twenty-four healthy subjects were enrolled and grouped into UGT2B15*1/*1 or UGT2B15*2/*2 genotype groups. The pharmacokinetic and pharmacodynamic profiles of intravenous lorazepam were characterized before and after inhibition with 600 mg valproate once daily for 4 days and after induction with rifampin (INN, rifampicin) pretreatment (600 mg once daily for 10 days), with a washout period of 10 days between. The plasma concentrations of lorazepam and lorazepam glucuronide were analyzed before and at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, and 48 hours after lorazepam administration by liquid chromatography-tandem mass spectrometry. Visual analog scale assessments and psychomotor coordination tests were administered before and up to 12 hours after drug administration. RESULTS: The UGT2B15*2/*2 group showed 0.58-fold (95% confidence interval, 0.43-0.72; P < .0001) lower systemic clearance during the basal state and 1.37-fold (95% confidence interval, 1.05-1.88; P = .037) higher area under the visual analog scale-time curve during the induced state compared with the UGT2B15*1/*1 group. The mean systemic clearance of lorazepam decreased by 20% in the inhibited state and increased by 140% in the induced state. During the inhibited or induced state, absolute values of clearance were consistently lower in the *2/*2 group, but the percent changes from baseline did not differ significantly by genotype. CONCLUSIONS: Our results suggest that the UGT2B15*2 polymorphism is a major determinant of interindividual variability with respect to the pharmacokinetics and pharmacodynamics of lorazepam.
ISSN
0009-9236 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15961980

http://hdl.handle.net/10371/22928
DOI
https://doi.org/10.1016/j.clpt.2005.02.006
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Pharmacology (약리학전공)Journal Papers (저널논문_약리학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse